GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,044 | 6,511 | 9,249 | 1,950 | 1,079 |
| Marketable Securities | N/A | N/A | N/A | 7,857 | 12,893 |
| TOTAL | $4,232 | $6,759 | $9,267 | $9,885 | $14,056 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 0 | 0 | 27 | 53 |
| TOTAL | $N/A | $N/A | $N/A | $27 | $53 |
| Total Assets | $4,232 | $6,759 | $9,267 | $9,912 | $14,109 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,853 | 2,612 | 1,717 | 3,213 | 4,328 |
| Accrued Expenses | 1,797 | 1,868 | 1,765 | 963 | 1,195 |
| Other current liabilities | 252 | 182 | 277 | 394 | 1,052 |
| TOTAL | $5,902 | $4,662 | $3,759 | $4,600 | $6,633 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,902 | $4,662 | $3,759 | $4,600 | $6,633 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,234 | 2,234 | 2,234 | 1,417 | 1,381 |
| Common Shares | 2 | 2 | 2 | 1 | 1 |
| Retained earnings | -695,227 | -691,452 | -688,041 | -684,331 | -682,065 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 1 |
| TOTAL | $-1,670 | $2,097 | $5,508 | $5,312 | $7,476 |
| Total Liabilities And Equity | $4,232 | $6,759 | $9,267 | $9,912 | $14,109 |